PTSD News

Brief psychological therapies delivered soon after traumatic childbirth may provide an opportunity to protect against childbirth-related PTSD symptoms, researchers reported.

Crisis response planning, a therapist-guided treatment for suicidal ideation, significantly reduced symptoms of suicidal ideation among U.S. military personnel and veterans, according to a study published in Journal of Anxiety Disorders.

The FDA has accepted and granted priority review to a new drug application for midomafetamine capsules used in combination with psychological intervention for PTSD, according to a press release from Lykos Therapeutics.

Patients who are hospitalized with stroke-like symptoms, but do not experience a stroke, may yet develop PTSD at a higher rate than patients who actually had a stroke, a speaker reported.

The American Psychiatric Association has selected Marketa Wills, MD, MBA, as its new CEO and medical director, effective June 1.

Silo Pharma will advance a portfolio of four drugs in its 2024 clinical pipeline, targeting conditions related to mental health, chronic pain and neurology.

A Houston-based neurohealth company has received a patent for its non-invasive, frequency-based deep brain stimulation device to address a range of psychiatric and neurologic conditions.

A biopharma company has received approval from the European Medicines Agency to commence a phase 1 clinical trial of its selective endocannabinoid reuptake inhibitor, which aims to restore healthy brain physiology.

The number of vacation days taken and time spent performing patient-related work while on vacation were associated with physician burnout, according to study results published in JAMA Network Open.

Patients with pulmonary fibrosis who used a smartphone app that offers cognitive behavioral therapy showed improvements in anxiety levels and quality of life, according to a press release.